Neurocrine Biosciences Total Long Term Liabilities 2010-2024 | NBIX

Neurocrine Biosciences total long term liabilities for the quarter ending September 30, 2024 were $0.386B, a 150.1% increase year-over-year.

  • Neurocrine Biosciences total long term liabilities for 2023 were $0.365B, a 195.94% increase from 2022.
  • Neurocrine Biosciences total long term liabilities for 2022 were $0.123B, a 72.79% decline from 2021.
  • Neurocrine Biosciences total long term liabilities for 2021 were $0.453B, a 7.27% increase from 2020.

Neurocrine Biosciences Total Long Term Liabilities 2010-2024 | NBIX

  • Neurocrine Biosciences total long term liabilities for 2023 were $0.365B, a 195.94% increase from 2022.
  • Neurocrine Biosciences total long term liabilities for 2022 were $0.123B, a 72.79% decline from 2021.
  • Neurocrine Biosciences total long term liabilities for 2021 were $0.453B, a 7.27% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$78.6B
Takeda Pharmaceutical (TAK)$44.1B
Merck (MKKGY)$21.2B
Astellas Pharma (ALPMY)$20.4B
Sandoz Group AG (SDZNY)$19.7B
United Therapeutics (UTHR)$18B
Summit Therapeutics (SMMT)$15.6B
Shionogi (SGIOY)$12.5B
Catalent (CTLT)$10.9B
Madrigal Pharmaceuticals (MDGL)$7.7B
Jazz Pharmaceuticals (JAZZ)$7.4B
Orion OYJ (ORINY)$6.8B
Ionis Pharmaceuticals (IONS)$6.1B
Corcept Therapeutics (CORT)$5.7B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.3B
Dyne Therapeutics (DYN)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.5B
NewAmsterdam Pharma (NAMS)$2B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Harrow (HROW)$1.8B
Ocular Therapeutix (OCUL)$1.7B
Xencor (XNCR)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B
ARS Pharmaceuticals (SPRY)$1.6B
Avadel Pharmaceuticals (AVDL)$1.5B